ATE468355T1 - Diabody-typ bispezifischer antikörper - Google Patents

Diabody-typ bispezifischer antikörper

Info

Publication number
ATE468355T1
ATE468355T1 AT03255113T AT03255113T ATE468355T1 AT E468355 T1 ATE468355 T1 AT E468355T1 AT 03255113 T AT03255113 T AT 03255113T AT 03255113 T AT03255113 T AT 03255113T AT E468355 T1 ATE468355 T1 AT E468355T1
Authority
AT
Austria
Prior art keywords
bispecific antibodies
type bispecific
diabody type
specificity
diabody
Prior art date
Application number
AT03255113T
Other languages
English (en)
Inventor
Izumi Kumagai
Toshio Kudo
Kouhei Tsumoto
Ryutaro Asano
Original Assignee
Tohoku Techno Arch Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku Techno Arch Co Ltd filed Critical Tohoku Techno Arch Co Ltd
Application granted granted Critical
Publication of ATE468355T1 publication Critical patent/ATE468355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
AT03255113T 2003-02-17 2003-08-18 Diabody-typ bispezifischer antikörper ATE468355T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003038643A JP3803790B2 (ja) 2003-02-17 2003-02-17 新規なダイアボディ型二重特異性抗体

Publications (1)

Publication Number Publication Date
ATE468355T1 true ATE468355T1 (de) 2010-06-15

Family

ID=32821088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03255113T ATE468355T1 (de) 2003-02-17 2003-08-18 Diabody-typ bispezifischer antikörper

Country Status (5)

Country Link
US (1) US7635475B2 (de)
EP (1) EP1454917B1 (de)
JP (1) JP3803790B2 (de)
AT (1) ATE468355T1 (de)
DE (1) DE60332596D1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
MXPA06009253A (es) 2004-02-16 2007-04-18 Micromet Ag Moleculas de enlace menos inmunogenicas.
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
JP5082104B2 (ja) * 2006-03-23 2012-11-28 国立大学法人東北大学 高機能性二重特異性抗体
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
CA2682626A1 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
JP5791895B2 (ja) 2007-05-04 2015-10-07 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 遺伝子操作されたウサギ抗体可変ドメイン及びその使用
CN103159857B (zh) * 2007-05-21 2014-11-05 财团法人工业技术研究院 以重组的三股螺旋支架为基础的复合物
EP2132228B1 (de) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US9315584B2 (en) 2009-03-25 2016-04-19 Tohoku University LH-type bispecific antibody
KR20120044294A (ko) * 2009-05-01 2012-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
EP2502936B1 (de) 2009-11-18 2016-01-06 Tohoku University Hochfunktioneller mutant variabler regionen des humanen anti-egfr-antikörpers
AU2011235867B2 (en) * 2010-04-01 2015-12-03 Kalobios Pharmaceuticals, Inc. EphA3 antibodies for the treatment of multiple myeloma
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) * 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112014009803B1 (pt) 2011-10-24 2021-07-06 Aditya Birla Nuvo Limited processo para produzir um negro de fumo modificado na superfície
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
US9410042B2 (en) 2012-03-30 2016-08-09 Aditya Birla Science And Technology Company Ltd. Process for obtaining carbon black powder with reduced sulfur content
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
WO2014151649A1 (en) * 2013-03-15 2014-09-25 Alper Biotech, Llc Monoclonal antibodies to egfr, and uses therefor
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US20170274072A1 (en) * 2014-03-26 2017-09-28 Tohoku University Bispecific antibody targeting human epidermal growth factor receptor
CN107073116A (zh) 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN105820251B (zh) * 2015-01-08 2019-10-15 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
AU2016219785B2 (en) 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
CN108367057B (zh) * 2015-04-06 2022-11-22 赛通免疫股份有限公司 用于胶质母细胞瘤的egfr导向的car疗法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3112381A1 (de) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Bispezifische antikörper zur verwendung in der krebsimmuntherapie
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP2019146524A (ja) * 2018-02-27 2019-09-05 出光興産株式会社 高発現かつ高機能な二重特異性抗体
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
US20210380679A1 (en) 2018-10-11 2021-12-09 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
AU2019414793A1 (en) 2018-12-26 2021-06-24 Innate Pharma Compounds and methods for treatment of head and neck cancer
CN113874399A (zh) * 2019-05-23 2021-12-31 维洛斯生物股份有限公司 抗ror1/抗cd3双特异性结合分子
US20220281998A1 (en) * 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
WO2023110918A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
US20240091262A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP4467188B2 (ja) * 1998-10-21 2010-05-26 アルター・バイオサイエンス・コーポレーション 多重特異的結合分子とその使用
AU2000257080A1 (en) 2000-06-30 2002-01-30 Tohoku Techno Arch Co., Ltd. Fused protein with antitumor effect

Also Published As

Publication number Publication date
EP1454917B1 (de) 2010-05-19
US7635475B2 (en) 2009-12-22
EP1454917A3 (de) 2005-04-06
JP2004242638A (ja) 2004-09-02
JP3803790B2 (ja) 2006-08-02
EP1454917A2 (de) 2004-09-08
DE60332596D1 (de) 2010-07-01
US20060210564A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
ATE468355T1 (de) Diabody-typ bispezifischer antikörper
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
ATE486610T1 (de) Anti-glypican-3-antikörper
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
ATE495248T1 (de) Monoklonaler anti-cd20-antikörper
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
LTPA2016007I1 (lt) Imunoglobulino chimeriniai monomero-dimero hibridai
ATE520716T1 (de) Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften
PE20150222A1 (es) Anticuerpos multiespecificos
ATE450549T1 (de) Monoklonale antikörper mit spezifität für fetale erythroidzellen
TW200636064A (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
DK1308507T3 (da) Monoklonalt antistof mod HCV-kerneantigen
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
WO2004029092A8 (fr) Anticorps pour adcc et induisant la production de cytokines.
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
CY1106594T1 (el) Αντισωματα εναντι ανθρωπινης il-12
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ITFI930246A1 (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
ATE443723T1 (de) Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
WO2005047456A3 (en) Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties